clinical trial · NCT06022757
Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19)
Evopoint Biosciences Inc.·phase2·recruiting·n = 204
CarcinomaSquamous Cell Carcinoma of Head and NeckUrothelial CarcinomaProstate CancerSmall-cell Lung CancerNon-small Cell Lung CancerCervical CancerOther Solid TumorsXNW5004KEYTRUDA® (pembrolizumab) 25 mg/mL Solution for Injection
brief summary
In this study, participants with different types of advanced solid tumors who failed standard treatments will be treated with XNW5004 in combination with KEYTRUDA® (pembrolizumab) .
started
Sep 20, 2023
primary completion
Aug 1, 2028
completion
Aug 1, 2028
last updated
Feb 23, 2024
official title
A Phase Ib/II Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol